Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)

Diffuse Large B-Cell Lymphoma (DLBCL) Clinical Trial

Official title:

A Phase II, Single-arm, Multicenter Trial to Evaluate the Efficacy and Safety of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04456023
• Other study ID #: CCTL019C2203
• Status: Withdrawn
• Phase: Phase 2
• Start date: January 31, 2022
• Est. completion date: September 27, 2027

Study information

• Verified date: February 2022
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multi-center, phase II study to evaluate the efficacy and safety of CTL019 in Chinese adult patients with relapsed or refractory DLBCL.

Description:

Disease assessments will be performed at screening, after bridging, 1, 3, 6, 9 and 12 months after tisagenlecleucel infusion, and every 6 months in the second year, and annually up to 60 months after infusion. Efficacy will be assessed until progression; safety will be assessed throughout the study. A long term follow-up up to 15 years after CTL019 infusion will continue under a separate protocol (CCTL019A2205B)(NCT02445222).

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: September 27, 2027
• Est. primary completion date: October 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed informed consent must be obtained prior to participation in the study

2. Patients must be =18 years of age at the time of ICF signature

3. Histologically confirmed DLBCL at last relapse (including DLBCL transformed from follicular lymphoma and double-triple hit lymphoma)

4. Relapsed or refractory disease after at least 2 lines of systemic therapy, including anti-CD20 antibody and an anthracycline, or having failed or being ineligible for autologous HSCT

5. ECOG performance status that is either 0 or 1 at screening

6. Measurable disease at time of enrollment:

• Nodal lesions greater than 15 mm in the long axis, regardless of the length of the short axis or

• Extra nodal lesion (outside lymph node or nodal mass, but including liver and spleen) at least 10 mm in long and short axis

7. Adequate organ function

8. Must have a leukapheresis material of non-mobilized cells available for manufacturing

Exclusion Criteria:

1. Prior treatment with anti-CD19 therapy, adoptive T cell therapy, or any prior gene therapy product

2. Primary mediastinal large B-cell lymphoma, EBV+ DLBCL, Richter's transformation, Burkitt lymphoma, primary DLBCL of CNS, T cell / histiocyte rich large B-cell lymphoma, primary cutaneous DLBCL.

3. Eligible for and consenting to autologous HSCT

4. Prior allogeneic SCT

5. Active CNS involvement by disease under study, except if the CNS involvement has been effectively treated (i.e. patient is asymptomatic) and local treatment was greater than 4 weeks before enrollment

6. Active neurological autoimmune or inflammatory disorders (e.g. Guillain-Barre syndrome)

7. Investigational medicinal product within the last 30 days or five half-lives (whichever is longer) prior to screening

Related Conditions & MeSH terms

• Diffuse Large B-Cell Lymphoma (DLBCL)
• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Large B-Cell, Diffuse
• Lymphoma, Non-Hodgkin

Intervention

Biological:
• Tisagenlecleucel
A single intravenous (i.v.) infusion of 0.6 - 6.0×10^8 CAR positive viable T cells.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Response Rate (ORR)	Complete Response (CR) and Partial Response (PR) according to the Lugano classification as determined by the Investigator.	From first dosing (single administration, Day 1) up to End of Study Visit (EOS), an average of 60 Months
Secondary	Duration of Response (DOR)	Time from CR or PR, whichever occurs first, to relapse or death due to DLBCL.	From first dosing (single administration, Day 1) up to End of Study Visit (EOS), an average of 60 Months
Secondary	Time to response (TTR)	Time from tisagenlecleucel infusion to CR or PR, whichever occurs first.	From first dosing (single administration, Day 1) up to End of Study Visit (EOS), an average of 60 Months
Secondary	Progression-Free Survival (PFS)	Time from tisagenlecleucel infusion to the first documented disease progression or death due to any cause.	From first dosing (single administration, Day 1) up to End of Study Visit (EOS), an average of 60 Months
Secondary	Event free survival (EFS)	Time from tisagenlecleucel infusion to the first documented disease progression or relapse, new treatment for lymphoma or death due to any cause.	From first dosing (single administration, Day 1) up to End of Study Visit (EOS), an average of 60 Months
Secondary	Overall Survival (OS)	Time from tisagenlecleucel infusion to death due to any cause.	From first dosing (single administration, Day 1) up to End of Study Visit (EOS), an average of 60 Months
Secondary	Number of Participants with On-Treatments Adverse Events, Serious Adverse Events, and Deaths	Analysis of absolute and relative frequencies for treatment emergent AE, SAE and Deaths by primary System Organ Class (SOC) through the monitoring of relevant clinical and laboratory safety parameters.	From first dosing (single administration, Day 1) up to End of Study Visit (EOS), an average of 60 Months
Secondary	Tisagenlecleucel immunogenicity (humoral)	The humoral immunogenicity assay will be evaluated to measure the antibody titers specific to the tisagenlecleucel molecule prior to and following infusion.	Up to Month 60
Secondary	Tisagenlecleucel immunogenicity (cellular)	The cellular immunogenicity assay will be evaluated to assess the presence of T lymphocytes activated by the tisagenlecleucel protein.	Up to Month 60
Secondary	In vivo cellular PK profile of tisagenelecleucel	qPCR and flow cytometry to measure tisagenlecleucel transgene concentration in blood, bone marrow and other matrices/tissues.	Up to Month 60
Secondary	Concentration of Tocilizumab PK in tocilizumab treated subjects during CRS	Concentration of Tocilizumab	Up to Day 7 after tocilizumab infusion
Secondary	Serum cytokines (IL-10, interferon gamma, IL-6, CRP and ferritin)	Concentration of soluble factors (IL-10, interferon gamma, IL-6, CRP and ferritin) will be listed and summarized by participant and time point.	Up to Month 60